GS

Girish Singh Chamyal Bisht

Active Director Director DIN 10626074
DIN 10626074 First appointment Apr 2024 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Girish Singh Chamyal Bisht

Data last updated:

Girish Singh Chamyal Bisht is a Director at Dolcas Biotech India Private Limited (since 2024). The company operates in Healthcare.

DIN 10626074
Primary Designation Director
Industry Healthcare
First Appointment 27 Apr 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Dolcas Biotech India Private Limited U86900DL2024PTC428453
Director27 Apr 20242024Active

Board colleagues of Girish Singh Chamyal Bisht

NameDINCompanyDesignation
Mulay Chandu Shashank10537050Dolcas Biotech India Private LimitedDirector

Directorship timeline

Open interactive timeline →
Dolcas Biotech India Private Limited
Premium access

Shareholding and investment profile for Girish Singh Chamyal Bisht

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Girish Singh Chamyal Bisht

Girish Singh Chamyal Bisht currently holds 1 directorship: Dolcas Biotech India Private Limited (Director, since 27 Apr 2024).

Girish Singh Chamyal Bisht was first appointed on 27 Apr 2024 as Director at Dolcas Biotech India Private Limited.

The current boards of Girish Singh Chamyal Bisht's companies include Mulay Chandu Shashank (Dolcas Biotech India Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available